Q
QuantAbundance

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

30,897 signal articles · 66 in last 24h · 157,635 total before filter · latest 13h ago
66last 24h
778last 7d
119● bullish (7d)
76● bearish (7d)
214publishers
AllMacro182Earnings131M&A86Regulatory15Product14Analyst22
✕ clear all filterssentiment: bullishSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
1 S&P 500 Stock on Our Buy List and 2 We Avoid
StockStory45d agobullish
1 S&P 500 Stock on Our Buy List and 2 We Avoid

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.

Stripe, Advent in Talks to Buy PayPal
The Wall Street Journal45d agobullish
Stripe, Advent in Talks to Buy PayPal

PayPal Holdings is in talks to sell itself to a group that includes Stripe and the private-equity firm Advent International, according to people familiar with the matter. Stripe and Advent in July proposed paying $60.50 a share for PayPal, a price PayPal viewed as insufficient, some of the people said.

Waymo doubles down on the cars America won’t let you buy
TheStreet45d agobullish
Waymo doubles down on the cars America won’t let you buy

Trade barriers are supposed to be simple machines. You raise the price of a thing until buying it stops making sense, and the buying stops. Washington built one of the tallest of those walls in modern trade policy around Chinese electric vehicles, and by the only measure most people can see, it ...

Bristol Myers Squibb (BMY) Wins FDA Approval, Is The Stock Fully Priced?
Simply Wall St.45d agobullish
Bristol Myers Squibb (BMY) Wins FDA Approval, Is The Stock Fully Priced?

Bristol Myers Squibb (BMY) is back in focus after the FDA granted accelerated approval for ZENBEXUS in a multiple myeloma combination regimen, introducing the first approved CELMoD therapy in this disease setting. See our latest analysis for Bristol-Myers Squibb. The ZENBEXUS approval lands at a time when Bristol-Myers Squibb’s momentum has picked up, with the share price at US$64.65 and a 30 day share price return of 13.52%. That builds on a 20.93% year to date share price return and a...